

CITATION REPORT

List of articles citing

Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis

DOI: 10.1111/apt.12695

Alimentary Pharmacology and Therapeutics, 2014, 39, 1113-25

Source: <https://exaly.com/paper-pdf/59286181/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
209	Microbiome: the bacterial tightrope. 2014 , 516, S14-6		17
208	Commentary: Probing probiotics in cirrhosis--a template for future studies?. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 1334-5	6.1	2
207	The role of microbiota in hepatic encephalopathy. 2014 , 5, 397-403		100
206	Commentary: Probing probiotics in cirrhosis--a template for future studies? Author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 1335-6	6.1	1
205	Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. 2014 , 147, 1327-37.e3		220
204	[Correlation of the microbiota and intestinal mucosa in the pathophysiology and treatment of irritable bowel, irritable eye, and irritable mind syndrome]. 2014 , 155, 1454-60		2
203	Application of Metabolomics to Assess Effects of Controlled Dietary Interventions. 2015 , 4, 365-376		2
202	Does low-dose rifaximin ameliorate endotoxemia in patients with liver cirrhosis: a prospective study. 2015 , 16, 665-74		6
201	Probiotics in Pediatric Liver Disease. 2015 , 49 Suppl 1, S33-6		9
200	A fresh look into the pathophysiology of ischemia-induced complications in patients with chronic kidney disease undergoing hemodialysis. 2015 , 8, 25-8		1
199	Gut microbiota and liver diseases. 2015 , 21, 1691-702		94
198	Inflammation: A novel target of current therapies for hepatic encephalopathy in liver cirrhosis. 2015 , 21, 11815-24		34
197	Fecal transplant to mitigate hyperammonemia and hepatic encephalopathy in animal models. 2015 , 14, 762-763		2
196	Gut microbiota and host metabolism in liver cirrhosis. 2015 , 21, 11597-608		68
195	Current evidence on the use of probiotics in liver diseases. 2015 , 17, 137-151		24
194	Gut microbiota, cirrhosis, and alcohol regulate bile acid metabolism in the gut. 2015 , 33, 338-45		58
193	Microbiome and complications of liver disease. 2015 , 5, 96-99		3

192	The role of probiotics in the prevention of severe infections following abdominal surgery. 2015 , 46 Suppl 1, S2-4	5
191	Circulating muramyl dipeptide is negatively associated with interleukin-10 in the frail elderly. 2015 , 38, 272-7	12
190	Covert and Overt Hepatic Encephalopathy: Diagnosis and Management. 2015 , 13, 2048-61	105
189	Alcoholic liver disease: the gut microbiome and liver cross talk. 2015 , 39, 763-75	151
188	Refining the ammonia hypothesis: a physiology-driven approach to the treatment of hepatic encephalopathy. 2015 , 90, 646-58	94
187	Recent advances in the treatment of hyperammonemia. 2015 , 90, 55-68	65
186	Is it time to target gut dysbiosis and immune dysfunction in the therapy of hepatic encephalopathy?. 2015 , 9, 539-42	23
185	Probiotics can improve the clinical outcomes of hepatic encephalopathy: An update meta-analysis. 2015 , 39, 674-82	26
184	Clinical and pathophysiological consequences of alterations in the microbiome in cirrhosis. 2015 , 110, 1399-410; quiz 1411	29
183	Gut microbiota: its role in hepatic encephalopathy. 2015 , 5, S29-36	94
182	Transcriptomic Profile of Whole Blood Cells from Elderly Subjects Fed Probiotic Bacteria <i>Lactobacillus rhamnosus</i> GG ATCC 53103 (LGG) in a Phase I Open Label Study. 2016 , 11, e0147426	16
181	Doses <i>Lactobacillus reuteri</i> depend on adhesive ability to modulate the intestinal immune response and metabolism in mice challenged with lipopolysaccharide. 2016 , 6, 28332	20
180	Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. 2016 , 311, G1018-G1036	49
179	Gastroenterology Disease and Lifestyle Medicine. 2016 , 333-340	
178	Profile of Gut Microbiota Associated With the Presence of Hepatocellular Cancer in Patients With Liver Cirrhosis. 2016 , 48, 1687-91	105
177	HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 638-43	6.1 38
176	Recent developments in the diagnosis and treatment of covert/minimal hepatic encephalopathy. 2016 , 10, 443-50	10
175	Mechanisms and therapeutic effectiveness of lactobacilli. 2016 , 69, 187-203	125

174	Targeting Dysbiosis for the Treatment of Liver Disease. 2016 , 36, 37-47	30
173	The Role of Probiotics on the Microbiota: Effect on Obesity. 2016 , 31, 387-400	32
172	The Gut Microbiome and Cirrhosis: Clinical Aspects. 2016 , 169-184	
171	Clinical science workshop: targeting the gut-liver-brain axis. 2016 , 31, 1327-1337	16
170	Serum Bile Acids Are Associated with Pathological Progression of Hepatitis B-Induced Cirrhosis. 2016 , 15, 1126-34	46
169	The Mexican consensus on probiotics in gastroenterology. 2017 , 82, 156-178	17
168	Gut Microbiota and Complications of Liver Disease. 2017 , 46, 155-169	54
167	Probiotics for people with hepatic encephalopathy. 2017 , 2, CD008716	48
166	Omics for Understanding the Gut-Liver-Microbiome Axis and Precision Medicine. 2017 , 6, 176-185	14
165	The Mexican consensus on probiotics in gastroenterology. 2017 , 82, 156-178	2
164	Effects of continuous use of probiotics before liver transplantation: A randomized, double-blind, placebo-controlled trial. 2017 , 36, 1530-1539	33
163	Gut microbiota changes and chronic hepatitis C virus infection. 2017 , 11, 813-819	48
162	The Effects of Probiotics and Symbiotics on Risk Factors for Hepatic Encephalopathy: A Systematic Review. 2017 , 51, 312-323	21
161	The interaction between smoking, alcohol and the gut microbiome. 2017 , 31, 579-588	94
160	Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. 2017 , 66, 1727-1738	307
159	Microbiome and metabolome data integration provides insight into health and disease. 2017 , 189, 51-64	49
158	The Impact of Gut Microbiota on Liver Injury. 2017 , 251-283	
157	An Overview of Probiotic Research. 2017 , 293-357	1

156	Microbiome, probiotics and neurodegenerative diseases: deciphering the gut brain axis. 2017 , 74, 3769-3787	244
155	Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. 2017 , 30, 191-231	41
154	Lactulose reduces bacterial DNA translocation, which worsens neurocognitive shape in cirrhotic patients with minimal hepatic encephalopathy. 2017 , 37, 212-223	17
153	Gut microbiome and liver disease. 2017 , 179, 49-59	58
152	Does Nutrition Matter in Liver Disease?. 2017 , 743-759	2
151	Lactobacillus rhamnosus GG. 2017 , 79-88	8
150	Bile acids at the cross-roads of gut microbiome-host cardiometabolic interactions. 2017 , 9, 102	32
149	Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step. 2017 , 5, 249-260	29
148	Gut : liver : brain axis: the microbial challenge in the hepatic encephalopathy. 2018 , 9, 1373-1388	35
147	Effect of Lactobacillus rhamnosus GG Supplementation on Intestinal Inflammation Assessed by PET/MRI Scans and Gut Microbiota Composition in HIV-Infected Individuals. 2018 , 78, 450-457	18
146	Effect of probiotic treatment on cirrhotic patients with minimal hepatic encephalopathy: A meta-analysis. 2018 , 17, 9-16	23
145	Diagnosis and management of hepatic encephalopathy. 2018 , 27, S7-S13	6
144	The Gut-Liver Axis in Hepatitis C Virus Infection: A Path Towards Altering the Natural History of Fibrosis Progression?. 2018 , 67, 878-880	1
143	Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg. 2018 , 12, 24-33	75
142	Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 192-202	6.1 101
141	Microbiota, Liver Diseases, and Alcohol. 2017 , 5,	12
140	Effect of probiotics and synbiotics consumption on serum concentrations of liver function test enzymes: a systematic review and meta-analysis. 2018 , 57, 2037-2053	23
139	Comprehensive preoperative regime of selective gut decontamination in combination with probiotics, and smectite for reducing endotoxemia and cytokine activation during cardiopulmonary bypass: A pilot randomized, controlled trial. 2018 , 97, e12685	0

138 Intestinal Microbiome and the Liver. **2018**, 37-65.e6

137 Implications of Probiotics on the Maternal-Neonatal Interface: Gut Microbiota, Immunomodulation, and Autoimmunity. **2018**, 9, 2840

24

136 Oral Dysbiosis in Pancreatic Cancer and Liver Cirrhosis: A Review of the Literature. **2018**, 6,

30

135 Editorial: direct anti-viral agents, hepatitis C virus eradication, and gut-liver axis-another mechanistic piece to the puzzle. *Alimentary Pharmacology and Therapeutics*, **2018**, 48, 1321-1322

6.1

134 The burden of minimal hepatic encephalopathy: from diagnosis to therapeutic strategies. **2018**, 31, 151-164

28

133 Current Applications of Metabolomics in Cirrhosis. **2018**, 8,

4

132 Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics. **2018**, 56, 855-867

21

131 Microbiota, Liver Diseases, and Alcohol. **2018**, 187-212

1

130 Role of probiotics in the treatment of minimal hepatic encephalopathy in patients with HBV-induced liver cirrhosis. **2018**, 46, 3596-3604

37

129 Essential Fatty Acids Linoleic Acid and α -Linolenic Acid Sex-Dependently Regulate Glucose Homeostasis in Obesity. **2018**, 62, e1800448

14

128 Efficacy of different drugs in the treatment of minimal hepatic encephalopathy: A network meta-analysis involving 826 patients based on 10 randomized controlled trials. **2018**, 119, 8336-8345

6

127 Management of refractory cirrhotic ascites: challenges and solutions. **2018**, 10, 55-71

11

126 Harnessing the Power of Microbiome Assessment Tools as Part of Neuroprotective Nutrition and Lifestyle Medicine Interventions. **2018**, 6,

15

125 The Pharmabiotic Approach to Treat Hyperammonemia. **2018**, 10,

43

124 Current Management of Hepatic Encephalopathy. **2018**, 113, 1600-1612

29

123 Metabolomics and Lipidomics Approaches in the Science of Probiotics: A Review. **2018**, 21, 1086-1095

17

122 Effectiveness of Multistrain Versus Single-strain Probiotics: Current Status and Recommendations for the Future. **2018**, 52 Suppl 1, Proceedings from t, S35-S40

43

121 The role of the gut microbiome in chronic liver disease: the clinical evidence revised. **2019**, 1, 214-226

41

120	Supplementation with Synbiotics and/or Branched Chain Amino Acids in Hepatic Encephalopathy: A Pilot Randomised Placebo-Controlled Clinical Study. 2019 , 11,	20
119	Analysis of the Relationship Between the Degree of Dysbiosis in Gut Microbiota and Prognosis at Different Stages of Primary Hepatocellular Carcinoma. 2019 , 10, 1458	32
118	Probiotics for Alleviating Alcoholic Liver Injury. 2019 , 2019, 9097276	14
117	The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. 2019 , 11,	42
116	Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: A multicenter, randomized controlled trial. 2019 , 20, 547-556	21
115	Fibroblast growth factor 21 is required for the therapeutic effects of Lactobacillus rhamnosus GG against fructose-induced fatty liver in mice. 2019 , 29, 145-157	14
114	Lactulose drives a reversible reduction and qualitative modulation of the faecal microbiota diversity in healthy dogs. 2019 , 9, 13350	7
113	Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature. 2019 , 20,	131
112	The role of gut microbiota in liver disease development and treatment. 2019 , 3, 3-18	24
111	Hepatocellular Cancer Induced by Infection. 2019 , 247-259	
110	Effect of a Multistrain Probiotic on Cognitive Function and Risk of Falls in Patients With Cirrhosis: A Randomized Trial. 2019 , 3, 632-645	28
109	Role of the intestinal microbiome in liver fibrosis development and new treatment strategies. 2019 , 209, 22-38	18
108	Effects of probiotic therapy on serum inflammatory markers: A systematic review and meta-analysis. 2019 , 54, 466-478	12
107	Specific Gut and Salivary Microbiota Patterns Are Linked With Different Cognitive Testing Strategies in Minimal Hepatic Encephalopathy. 2019 , 114, 1080-1090	27
106	Altered Microbiome in Patients With Cirrhosis and Complications. 2019 , 17, 307-321	64
105	Rifaximin-altered gut microbiota components associated with liver/neuropsychological functions in patients with hepatic encephalopathy: An exploratory data analysis of phase II/III clinical trials. 2019 , 49, 404-418	15
104	Cross-species examination of single- and multi-strain probiotic treatment effects on neuropsychiatric outcomes. 2019 , 99, 160-197	11
103	Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. 2019 , 13, 193-204	39

102	Bifidobacterium adolescentis CGMCC 15058 alleviates liver injury, enhances the intestinal barrier and modifies the gut microbiota in D-galactosamine-treated rats. 2019 , 103, 375-393	20
101	How to Design a Multicenter Clinical Trial in Hepatic Encephalopathy. 2019 , 9, 137-145	6
100	Effect of probiotic and synbiotic supplementation on inflammatory markers in health and disease status: A systematic review and meta-analysis of clinical trials. 2020 , 39, 789-819	44
99	The effect of probiotics on inflammatory biomarkers: a meta-analysis of randomized clinical trials. 2020 , 59, 633-649	31
98	Probiotic Lactobacillus rhamnosus GG Prevents Liver Fibrosis Through Inhibiting Hepatic Bile Acid Synthesis and Enhancing Bile Acid Excretion in Mice. 2020 , 71, 2050-2066	62
97	Gut microbiota is associated with adiposity markers and probiotics may impact specific genera. 2020 , 59, 1751-1762	7
96	Comparative Efficacy of Treatment Options for Minimal Hepatic Encephalopathy: A Systematic Review and Network Meta-Analysis. 2020 , 18, 800-812.e25	18
95	Manipulation of microbiota with probiotics as an alternative for treatment of hepatic encephalopathy. 2020 , 73, 110693	5
94	Metagenomic analysis reveals distinct patterns of gut lactobacillus prevalence, abundance, and geographical variation in health and disease. 2020 , 12, 1-19	9
93	Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis. 2020 , 21,	16
92	Non-Lactulose Medication Therapies for the Management of Hepatic Encephalopathy: A Literature Review. 2021 , 34, 922-933	0
91	An Update on the Efficacy and Functionality of Probiotics for the Treatment of Non-Alcoholic Fatty Liver Disease. 2020 , 7, 679-679	2
90	The Microbiome and Hepatocellular Carcinoma. 2020 , 26, 1316-1327	14
89	A Double-Blind, Randomized Placebo-Controlled Trial of Probiotic Shirota in Stable Cirrhotic Patients. 2020 , 12,	12
88	Altered faecal microbiota on the expression of Th cells responses in the exacerbation of patients with hepatitis E infection. 2020 , 27, 1243-1252	8
87	A story of liver and gut microbes: how does the intestinal flora affect liver disease? A review of the literature. 2020 , 318, G889-G906	43
86	Novel Therapies in Hepatic Encephalopathy. 2020 , 24, 303-315	6
85	What diet should I recommend my patient with Hepatic Encephalopathy?. 2020 , 19, 13-22	3

84	Microbiome: Emerging Concepts in Patients with Chronic Liver Disease. 2020 , 24, 493-520	2
83	Changes in the Intestinal Microbiome during a Multispecies Probiotic Intervention in Compensated Cirrhosis. 2020 , 12,	10
82	Lactobacillus rhamnosus GG Attenuates Lipopolysaccharide-Induced Inflammation and Barrier Dysfunction by Regulating MAPK/NF- κ B Signaling and Modulating Metabolome in the Piglet Intestine. 2020 , 150, 1313-1323	16
81	Gut Microbial Dysbiosis Is Associated With Profibrotic Factors in Liver Fibrosis Mice. 2020 , 10, 18	7
80	Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis. 2020 , 72, 1003-1027	65
79	Eicosapentaenoic and Docosahexaenoic Acids Differentially Alter Gut Microbiome and Reverse High-Fat Diet-Induced Insulin Resistance. 2020 , 64, e1900946	23
78	Probiotics treatment improves cognitive impairment in patients and animals: A systematic review and meta-analysis. 2021 , 120, 159-172	13
77	Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease. 2021 , 160, 556-572	17
76	The gut microbiota in hepatic encephalopathy. 2021 , 187-204	
75	Probiotics improve the neurometabolic profile of rats with chronic cholestatic liver disease. 2021 , 11, 2269	8
74	Translocation of gut microbiota in liver cirrhosis: mechanisms, clinical significance, and markers. 2021 , 23, 147-160	
73	Genetically engineered E. coli Nissle attenuates hyperammonemia and prevents memory impairment in bile-duct ligated rats. 2021 , 41, 1020-1032	1
72	The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD. 2021 , 135, 111235	5
71	Microbiota, Inflammation, and Gut Barrier Dysfunction in HCC.	1
70	Diet-Regulating Microbiota and Host Immune System in Liver Disease. 2021 , 22,	2
69	Current approach to treatment of minimal hepatic encephalopathy in patients with liver cirrhosis. 2021 , 27, 3050-3063	3
68	Butyrate administration strengthens the intestinal epithelium and improves intestinal dysbiosis in a cholestasis fibrosis model. 2021 ,	0
67	Microbiome therapeutics for hepatic encephalopathy. 2021 , 75, 1452-1464	7

66	Therapeutic Applications of Resveratrol in Hepatic Encephalopathy through Its Regulation of the Microbiota, Brain Edema, and Inflammation. 2021 , 10,	1
65	The effect of probiotics on cognitive function across the human lifespan: A systematic review. 2021 , 128, 311-327	6
64	The Potential of Probiotics to Eradicate Gut Carriage of Pathogenic or Antimicrobial-Resistant. 2021 , 10,	0
63	Eicosapentaenoic and docosahexaenoic acids attenuate hyperglycemia through the microbiome-gut-organs axis in db/db mice. 2021 , 9, 185	11
62	Probiotics in hepatology: An update. 2021 , 13, 1154-1166	3
61	Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases. 2021 , 27, 6161-6179	2
60	Mechanisms of Gut Microbiota Modulation by Food, Probiotics, Prebiotics and More. 2021 , 84-84	0
59	Gut microbiome changes in Nonalcoholic fatty liver disease & alcoholic liver disease. 2021 , 6, 3	9
58	Neurologic Consequences of Liver Disease. 2018 , 203-219.e6	1
57	Potential delivery routes of postbiotics. 2020 , 1-39	10
56	A different gut microbiome linked to inflammation found in cirrhotic patients with and without hepatocellular carcinoma	1
55	Microbiota, cirrhosis, and the emerging oral-gut-liver axis. 2017 , 2,	91
54	Microbial Infections as a Trigger for Acute-on-Chronic Liver Failure: A Review. 2019 , 25, 4773-4783	3
53	[Liver diseases: The pathogenetic role of the gut microbiome and the potential of treatment for its modulation]. 2017 , 89, 120-128	4
52	Microbiota, a key player in alcoholic liver disease. 2018 , 24, 100-107	49
51	The Role of the Gut Microbiome in Liver Cirrhosis Treatment. 2020 , 22,	12
50	EFFECT OF PROBIOTICS ON ALTERED GUT MICROFLORA IN PATIENTS WITH SEVERE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME. 2019 , 72,	1
49	Quality of life in patients with minimal hepatic encephalopathy. 2018 , 24, 5446-5453	28

48	Implication of the intestinal microbiome in complications of cirrhosis. 2016 , 8, 1128-1136	16
47	Microbiota shaping - the effects of probiotics, prebiotics, and fecal microbiota transplant on cognitive functions: A systematic review. 2021 , 27, 6715-6732	3
46	Ischemia-induced complications in patients with chronic kidney disease undergoing hemodialysis: Looking beyond hypoperfusion. 2014 , 2, 101-103	
45	Portosystemic Encephalopathy. 2017 , 481-506	
44	Cirrhotic ascites: A review of pathophysiology and management. 2020 , 12, 3	
43	GUT MICROBIOTA, PREBIOTICS, PROBIOTICS, AND SYNBIOTICS IN GASTROINTESTINAL AND LIVER DISEASES: PROCEEDINGS OF A JOINT MEETING OF THE BRAZILIAN SOCIETY OF HEPATOLOGY (SBH), BRAZILIAN NUCLEUS FOR THE STUDY OF HELICOBACTER PYLORI AND MICROBIOTA (NBSH), AND BRAZILIAN FEDERATION OF GASTROENTEROLOGY (FEG) 2020 , 57, 331-333	4
42	Gut Microbiome-Mediated Alteration of Immunity, Inflammation, and Metabolism Involved in the Regulation of Non-alcoholic Fatty Liver Disease. 2021 , 12, 761836	5
41	The Gastrointestinal Microbiome: Alcohol Effects on the Composition of Intestinal Microbiota. 2015 , 37, 223-36	114
40	The Microbiome and the Liver. 2014 , 10, 519-521	1
39	Gut Microbes and Hepatic Encephalopathy: From the Old Concepts to New Perspectives.. 2021 , 9, 748253	1
38	Influence of Probiotics Administration Before Liver Resection in Patients with Liver Disease: A Randomized Controlled Trial. 2021 , 1	2
37	Microbial Therapeutics in Liver Disease. 2021 ,	0
36	Probiotics and the gut-liver axis. 2022 , 467-481	
35	Therapeutic potential of <i>Saccharomyces boulardii</i> in liver diseases: from passive bystander to protective performer?. 2021 , 175, 106022	0
34	Empyema and bacteremia caused by <i>Aeromonas hydrophila</i> : Case report and review of the literature.. 2022 ,	0
33	High-throughput technologies in probiotics science. 2022 , 77-101	
32	EVC001 Is Well-Tolerated and Improves Human Milk Oligosaccharide Utilization in Preterm Infants in the Neonatal Intensive Care Unit.. 2021 , 9, 795970	2
31	Probiotics Exhibit Strain-Specific Protective Effects in T84 Cells Challenged With -Infected Fecal Water.. 2021 , 12, 698638	1

- 30 Gut Microbiome and Organ Fibrosis.. **2022**, 14, 1
- 29 The as a Probiotic: Focusing on Liver Diseases.. **2022**, 10, 1
- 28 Des probiotiques pour l'encéphalopathie hépatique. **2022**, N° 1, 19-26
- 27 Intestinal virome in patients with alcohol use disorder and after abstinence.. **2022**, 0
- 26 Role of Microbiota-Derived Metabolites in Alcoholic and Non-Alcoholic Fatty Liver Diseases.. **2021**, 23, 5
- 25 Data_Sheet_1.docx. **2020**,
- 24 Image_1.TIF. **2020**,
- 23 Table_1.DOCX. **2020**,
- 22 Image_1.TIF. **2019**,
- 21 Image_2.TIF. **2019**,
- 20 Microbiome Engineering for Metabolic Disorders. **2022**, 47-91
- 19 Characteristics and Clinical Significance of Intestinal Microbiota in Patients with Chronic Hepatitis B Cirrhosis and Type 2 Diabetes Mellitus. **2022**, 2022, 1-14
- 18 Cancer-Associated Microbiota: From Mechanisms of Disease Causation to Microbiota-Centric Anti-Cancer Approaches. **2022**, 11, 757 2
- 17 Trust Your Gut: The Association of Gut Microbiota and Liver Disease. **2022**, 10, 1045 0
- 16 Gut microbiota dysbiosis: The potential mechanisms by which alcohol disrupts gut and brain functions. 13, 0
- 15 The Link between Gut Microbiota and Hepatic Encephalopathy. **2022**, 23, 8999 0
- 14 The gut microbiota as a vehicle for the prevention and treatment of hepatocellular carcinoma. **2022**, 115225 0
- 13 Ameliorative effect of Lactobacillus rhamnosus GG on acetaminophen-induced hepatotoxicity via PKC/Nrf2/PGC-1 β pathway. **2022**, 20, 1

- 12 Gut microbiota modulation in acute decompensation of liver cirrhosis: theory and therapeutic potential. **2022**, 11, 65 ○
- 11 Minimal Hepatic Encephalopathy Affects Daily Life of Cirrhotic Patients: A Viewpoint on Clinical Consequences and Therapeutic Opportunities. **2022**, 11, 7246 ○
- 10 The Microbiome in Neurogastroenterology. **2022**, 73-93 ○
- 9 Role of gut microbiota in the pathogenesis and therapeutics of minimal hepatic encephalopathy via the gut-liver-brain axis. 29, 144-156 ○
- 8 Impact of a Single Dose of a Probiotic Nutritional Supplement (AB001) on Absorption of Ethylalcohol: Results From a Randomized Double-Blind Crossover Study. **2023**, 16, 117863882211411 ○
- 7 Alterations of gut microbiome and effects of probiotic therapy in patients with liver cirrhosis: A systematic review and meta-analysis. **2022**, 101, e32335 ○
- 6 Investigation of therapeutic effects of rhubarb decoction retention enema on minimal hepatic encephalopathy in rats based on 16S rDNA gene sequencing and bile acid metabolomics. **2023**, 230, 115392 ○
- 5 Gut Lactobacillus and Probiotics Lactobacillus lactis/rhamnosis Ameliorate Liver Fibrosis in Prevention and Treatment. **2023**, 61, 245-257 ○
- 4 Microbiome-liver crosstalk: A multihit therapeutic target for liver disease. 29, 1651-1668 ○
- 3 Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota. 14, ○
- 2 Update in the Treatment of the Complications of Cirrhosis. **2023**, ○
- 1 Therapeutic possibilities of gut microbiota modulation in acute decompensation of liver cirrhosis. 15, 525-537 ○